Publications by authors named "M G Crespo-Leiro"
Aims: No study has analyzed the impact of guideline-directed medical therapy in preventing heart failure (HF) relapse in patients with arrhythmia-induced cardiomyopathy (AiCM) following left ventricular ejection fraction (LVEF) improvement.
Methods And Results: We analyzed data from a single-center cohort of 200 patients admitted for HF, LVEF <50% and cardiac arrhythmia considered by cardiologists to be the precipitating cause of the episode. The primary endpoint was time-to-HF relapse, defined as the composite of readmission for HF, Emergency Department (ED) visit for HF, or significant decline in LVEF.
Background: There is a long-standing need for a noninvasive biomarker that allows monitoring of cardiac allograft rejection, avoiding the need for periodic endomyocardial biopsies (EMB).
Methods: Multicenter, observational, prospective study, performed between 2019 and 2023 (NCT04973943). All patients underwent 7 per-protocol surveillance EMB during the first postheart transplantation year.
Article Synopsis
- - The study evaluated cardiologists' awareness and implementation of advanced heart failure (HF) guidelines, revealing significant knowledge gaps, especially among general cardiologists and other participants compared to heart failure specialists.
- - An online survey collected data from 497 cardiologists across Europe, highlighting that 84% of heart failure cardiologists regularly used ESC/HFA criteria for advanced HF, while only 44% of general cardiologists did.
- - The findings emphasize the need for increased education on advanced HF guidelines and improvements in the referral process to ensure patients receive timely and appropriate care.
Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device's patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC.
Europace
November 2024
Article Synopsis
- Left ventricular assist devices (LVADs) are commonly used to treat advanced heart failure, improving survival but leading to high rates of arrhythmias (20-50%) within a year after implantation.
- Arrhythmias in these patients increase the risk of complications, such as additional shocks from implantable defibrillators and potential worsening of right ventricular failure, highlighting the need for tailored management strategies.
- Effective treatment for these arrhythmias may involve specialized approaches like catheter ablation, though unique challenges exist in accessing arrhythmogenic areas after LVAD surgery, making pre-implantation procedures potentially beneficial.
Background And Objective: Hyperkalemia (HK) is an electrolyte disturbance in the concentration of potassium ions (K), whose risk increases in patients with chronic kidney disease (CKD) or heart failure (HF) and/or in patients being treated with renin-angiotensin-aldosterone system inhibitors (RAASi). The new oral K chelators offer a safe and effective treatment to maintain normokalemia in these patients. The objective of the analysis is to estimate the cost-effectiveness of sodium zirconium cyclosilicate (SZC) for the treatment of chronic HK in patients with CKD or HF versus standard treatment (calcium polystyrene sulfonate and lifestyle modifications) from the perspective of the Spanish National Health System.
View Article and Find Full Text PDF